> Skip repeated content

HSS Research Institute

Retrospective Review of Education Programs for People with Musculoskeletal Disorders

IRB Number: 12046
(inactive trial)

Institutional Review Board, Hospital for Special Surgery

May 24, 2012

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Laura Robbins, DSW


Sandra Goldsmith, MA, MS, RD
Dana Friedman, MPH
Dana Sperber
Robyn M. Wiesel, CHES
Linda Roberts, LCSW
Huijuan Huang, MPA


HSS offers members of the community a variety of free or low-cost lectures and workshops, which meet either once a semester or over the course of several weeks if they are part of a series.  In this retrospective study, the efficacy of HSS-sponsored educational programs addressing musculoskeletal health between 2008-2011 will be evaluated to assess the impact of the different programs on participant knowledge of musculoskeletal diseases.  The target enrollment number for this study is 4,500.

Inclusion/Exclusion Criteria

Participants who attended any of the OAWI and OWI programs between 2008-2011 will be included in this study. Any English-speaking adult may participate in these programs – they need not be HSS patients to attend classes. 

Contact Information

Dana Friedman, MPH